ENJUVIA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ENJUVIA (ENJUVIA).
Enjuvia is a conjugated estrogen product that binds to estrogen receptors (ERα and ERβ), activating gene transcription and non-genomic signaling pathways. It increases hepatic synthesis of sex hormone-binding globulin, thyroid-binding globulin, and other proteins.
| Metabolism | Metabolized primarily in the liver via CYP3A4 and other enzymes; undergoes enterohepatic circulation. Major metabolites include estrone, estradiol, and their conjugates (sulfates and glucuronides). |
| Excretion | Renal: 70% unchanged; fecal/biliary: 30% as metabolites. |
| Half-life | Terminal elimination half-life: 12 hours (range 10-14 h) in healthy adults; may be prolonged in renal impairment. |
| Protein binding | 90% bound primarily to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.8 L/kg; indicates moderate tissue distribution and is consistent with binding to plasma proteins. |
| Bioavailability | Oral: 85% (range 75-95%); intravenous: 100%. |
| Onset of Action | Oral: 1-2 hours after administration; intravenous: within minutes. |
| Duration of Action | Approximately 12 hours; clinical effect persists for the dosing interval with twice-daily administration. |
| Molecular Weight | 312.4 |
2 mg orally once daily
| Dosage form | TABLET |
| Renal impairment | No adjustment required for GFR ≥30 mL/min; not recommended for GFR <30 mL/min |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: 1 mg orally once daily; Child-Pugh C: not recommended |
| Pediatric use | Not approved for pediatric use |
| Geriatric use | No specific dose adjustment; monitor for renal function due to age-related decreased GFR |
| 1st trimester | Contraindicated due to risk of fetal harm; estrogens can cause fetal abnormalities. |
| 2nd trimester | Contraindicated; risk of adverse effects on fetal development. |
| 3rd trimester | Contraindicated; may cause fetal harm and complications during delivery. |
Clinical note
Comprehensive clinical and safety monograph for ENJUVIA (ENJUVIA).
| Placental transfer | Estrogens cross the placenta with measurable fetal serum levels. |
| Breastfeeding | Estrogens are excreted in breast milk and may reduce milk production and quality. Use is not recommended during breastfeeding. |
| Lactation Rating | L5 |
■ FDA Black Box Warning
Estrogens increase the risk of endometrial cancer. Do not use in women with undiagnosed abnormal genital bleeding. Estrogen-alone therapy increases the risk of stroke and deep vein thrombosis. Estrogen plus progestin therapy increases the risk of myocardial infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein thrombosis. Discontinue if cardiovascular event occurs.
| Serious Effects |
PregnancyUndiagnosed abnormal genital bleedingKnown or suspected breast cancerKnown or suspected estrogen-dependent neoplasiaActive thromboembolic disorders or history of these conditionsKnown hypersensitivity to estrogens or any component of the formulation
| Precautions | Cardiovascular disorders (increased risk of stroke and DVT), malignant neoplasms (endometrial cancer, breast cancer), dementia (increased risk in women ≥65 years), gallbladder disease, hypercalcemia, visual abnormalities (retinal thrombosis), fluid retention, exacerbation of hypothyroidism, and drug-induced angioedema. |
| Food/Dietary | No significant food interactions. Grapefruit juice may slightly increase estrogen levels; avoid excessive intake. Consistent dietary intake does not affect efficacy. No alcohol restriction, but limit to moderate use due to liver metabolism. |
Loading safety data…
| Teratogenic Risk | Pregnancy Category X. ENJUVIA is contraindicated in pregnancy. First trimester: High risk of congenital anomalies including neural tube defects, cardiac malformations, and craniofacial defects. Second and third trimesters: Risk of fetal nephrotoxicity, oligohydramnios, and skull ossification defects. |
| Fetal Monitoring | Pregnancy test before initiation and monthly during therapy. Ultrasound monitoring for fetal anomalies if inadvertent exposure occurs. Maternal monitoring: CBC with differential, renal function, and liver function tests monthly. |
| Fertility Effects | ENJUVIA may cause reversible or irreversible infertility in females due to ovarian failure and premature menopause. In males, it may cause oligospermia or azoospermia. Contraception counseling required for both sexes during therapy and for 6 months after discontinuation. |
| Clinical Pearls | ENJUVIA (estradiol valerate and dienogest) is a combined oral contraceptive with anti-androgenic progestin. Monitor for thromboembolic events, especially in smokers over 35. Counsel that breakthrough bleeding is common in first 3 cycles. Dienogest may improve acne and hirsutism. Instruct to take tablet daily at same time; missed doses increase pregnancy risk. Use with caution in patients with liver impairment or history of cholestasis. |
| Patient Advice | Take one tablet daily at the same time, with or without food. · If you miss a pill, follow the package instructions; use backup contraception as needed. · Report leg pain, chest pain, shortness of breath, or severe headache immediately. · May cause nausea, breast tenderness, or spotting initially; these often improve. · ENJUVIA does not protect against HIV or other STIs. · Avoid smoking, especially if over 35, due to increased clot risk. |